Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Failed single-agent trial is small setback for Sutent, analyst says. Pfizer has three combination trials also ongoing in breast cancer settings.
You may also be interested in...
R&D In Brief
Pfizer halts figitumumab lung cancer trial: Pfizer has stopped a late-stage trial of its insulin-like growth factor 1 inhibitor figitumumab (CP-751,871) in metastatic non-small cell lung cancer, losing the lead in the new oncology space (1Pharmaceutical Approvals Monthly May 2008). Pfizer is continuing with an ongoing trial combining figitumumab with Roche/Genentech's Tarceva in NSCLC; a third planned Phase III trial has not yet started. The Phase III lung cancer trial was halted after the independent data safety monitoring board detected an imbalance in serious adverse events, including fatalities, in the '871, carboplatin and Taxol arm. Pfizer, which has made a major push into oncology, has faced other recent setbacks in cancer, with failed trials of Sutent (sunitinib) in breast cancer and the investigational axitinib in pancreatic cancer (2"The Pink Sheet" DAILY, April 2, 2009)
R&D In Brief
Pfizer halts figitumumab lung cancer trial: Pfizer has stopped a late-stage trial of its insulin-like growth factor 1 inhibitor figitumumab (CP-751,871) in metastatic non-small cell lung cancer, losing the lead in the new oncology space (1Pharmaceutical Approvals Monthly May 2008). Pfizer is continuing with an ongoing trial combining figitumumab with Roche/Genentech's Tarceva in NSCLC; a third planned Phase III trial has not yet started. The Phase III lung cancer trial was halted after the independent data safety monitoring board detected an imbalance in serious adverse events, including fatalities, in the '871, carboplatin and Taxol arm. Pfizer, which has made a major push into oncology, has faced other recent setbacks in cancer, with failed trials of Sutent (sunitinib) in breast cancer and the investigational axitinib in pancreatic cancer (2"The Pink Sheet" DAILY, April 2, 2009)
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.